Dedicated CKD Outcome Trial
Tirzepatide’s kidney outcomes data consist entirely of post-hoc analyses from the SURPASS programme and secondary outcomes from the SURMOUNT obesity trials. The absence of a dedicated, powered, prospective kidney outcomes trial is a significant evidence gap. By contrast, SGLT2 inhibitors (empagliflozin in EMPA-REG, dapagliflozin in DAPA-CKD, canagliflozin in CREDENCE) and GLP-1 receptor agonists (semaglutide in FLOW) have or are completing dedicated kidney outcome trials with pre-specified primary endpoints.
This matters because post-hoc analyses are prone to multiple comparisons, selective reporting, and are not powered to detect kidney outcomes specifically. The SURPASS-4 kidney data found tirzepatide nearly halved the composite kidney endpoint vs insulin glargine, but this analysis compared tirzepatide to insulin — a comparator that itself worsened albuminuria (+36.9% UACR increase). It is not known whether tirzepatide’s kidney effects are superior to, equivalent to, or inferior to SGLT2 inhibitors (the current first-line renoprotective agents in T2D guidelines).
Ontology Dedicated CKD Outcome Trial [evidence_gap_for] Tirzepatide Dedicated CKD Outcome Trial [relates] Kidney Outcomes Dedicated CKD Outcome Trial [relates] Type 2 Diabetes
Gap Detail
- What is claimed: Tirzepatide protects kidneys; reduces CKD progression risk
- What is known: Post-hoc HR 0.58 for composite kidney endpoint vs insulin glargine; reduced eGFR decline and UACR — consistent across multiple analyses
- What is unknown: Whether effect holds in pre-specified powered trial; how tirzepatide compares to SGLT2i or GLP-1 RAs with established renoprotection; effect in patients with eGFR <30 or macroalbuminuria
- Why this matters clinically: KDIGO and ADA guidelines require robust RCT evidence for formal renoprotective drug positioning; without it, tirzepatide cannot be recommended ahead of SGLT2i for CKD prevention
- Best available proxy: SURPASS-4 post-hoc (PMID 36152639); pooled UACR analyses
Connections
- Tirzepatide — evidence_gap_for
- Kidney Outcomes — relates
- Type 2 Diabetes — relates